Patient and provider perceptions of intentional medication discontinuation

患者和提供者对有意停药的看法

基本信息

  • 批准号:
    9768231
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-05-01 至 2019-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This is the second submission of a VA HSR&D CDA proposal to provide five years of salary support to Amy Linsky, MD, MSc toward her goal of developing into a VA independent investigator and expert on medication safety research. Dr. Linsky is a general internist and an investigator in the HSR&D Center for Organization, Leadership, and Management Research (COLMR) at VA Boston Healthcare System. This proposal delineates the research and training objectives that will lead to Dr. Linsky's maturation into an independent health services researcher while contributing to the fields of patient safety and quality of care, especially as thy pertain to appropriate medication use. The first proposed research objective will center on elucidating Veterans' and clinicians' perspectives on intentional medication discontinuation, a part of the prescribing process that to date has not been explored. Building on qualitative work in progress, Dr. Linsky will develop two survey instruments: one to elicit patients' attitudes and beliefs and the other to understand how clinicians view overmedication and potential medication discontinuation. Bringing the Veterans' preferences into clinical decision making is concordant with other efforts in the VA to promote patient-centered care. The VA is a vanguard of health information technology, with a well-established and integrated electronic health record. Despite this, medication discrepancies, with potential to cause serious harm to patients, persist. One type of discrepancy, therapeutic duplication, can lead to unintentional overdose. The second research objective proposes to identify the prevalence of this safety concern within VA nationally and to identify correlates of these duplications. To effect meaningful change in prescribing, the results of these first two research objectives will be combined with relevant findings in the literature to develop and pilot test an intervention intended to promote consideration of
描述(由申请人提供): 这是第二次提交VA HSR&D CDA提案,为Amy Linsky,MD,MSc提供五年的工资支持,以实现她发展成为VA独立调查员和药物安全研究专家的目标。Linsky博士是VA波士顿医疗保健系统HSR&D组织,领导和管理研究中心(COLMR)的普通内科医生和研究员。该提案描述了研究和培训目标,这些目标将使林斯基博士成为一名独立的卫生服务研究人员,同时为患者安全和护理质量领域做出贡献,特别是在适当的药物使用方面。 第一个拟议的研究目标将集中在阐明退伍军人和临床医生对故意停药的观点,这是迄今为止尚未探索的处方过程的一部分。在定性工作的基础上,Linsky博士将开发两种调查工具:一种是了解患者的态度和信念,另一种是了解临床医生如何看待过度用药和潜在的停药。将退伍军人的偏好纳入临床决策与退伍军人事务部促进以病人为中心的护理的其他努力是一致的。 VA是健康信息技术的先锋,拥有完善的综合电子健康记录。尽管如此,可能对患者造成严重伤害的用药差异仍然存在。一种类型的差异,治疗重复,可能导致无意过量。第二个研究目标是确定全国范围内VA的这种安全性问题的患病率,并确定这些重复的相关性。 为了在处方方面实现有意义的改变,前两个研究目标的结果将与文献中的相关发现相结合,以开发和试点测试旨在促进考虑以下因素的干预措施:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amy Linsky其他文献

Amy Linsky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amy Linsky', 18)}}的其他基金

Impact of COVID-19 on implementation and outcomes of VA's Life-Sustaining TreatmentDecisions Initiative
COVID-19 对 VA 生命维持治疗决策计划的实施和结果的影响
  • 批准号:
    10417471
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Engaging Patients to Promote Deprescribing
让患者参与促进取消处方
  • 批准号:
    10359059
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Engaging Patients to Promote Deprescribing
让患者参与促进取消处方
  • 批准号:
    10607989
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
药物协调工具安全消息传递 (SMMRT) 试用
  • 批准号:
    10027247
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
药物协调工具安全消息传递 (SMMRT) 试用
  • 批准号:
    10176578
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
药物协调工具安全消息传递 (SMMRT) 试用
  • 批准号:
    10179472
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Artificial intelligence-based health IT tools to optimize critical care pharmacist resources through adverse drug event prediction
基于人工智能的健康 IT 工具,通过药物不良事件预测来优化重症监护药剂师资源
  • 批准号:
    10503268
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases
普拉格雷和氯吡格雷出血风险的比较:使用药物不良事件报告数据库的回顾性研究
  • 批准号:
    18K14954
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Adverse Reactions to Potent Opioids: An analysis using the largescale Japanese Adverse Drug Event Report database
对强效阿片类药物的不良反应:使用大型日本药物不良事件报告数据库进行的分析
  • 批准号:
    15K08111
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Implementation and Evaluation of an Enhanced PharmaNet-Based Adverse Drug Event Reporting Platform to Improve Patient Safety and Meet Adverse Drug Reaction Reporting Requirements
基于 PharmaNet 的增强型药品不良事件报告平台的实施和评估,以提高患者安全并满足药品不良反应报告要求
  • 批准号:
    334597
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
  • 批准号:
    9123554
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Integration of spatial epidemiology and pharmacoepidemiology for the practical use of the adverse drug event report database with related applications
空间流行病学和药物流行病学的整合,用于药物不良事件报告数据库的实际使用及相关应用
  • 批准号:
    26540012
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
  • 批准号:
    8772667
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Epidemiology of Adverse Drug Event in intensive care unit (ICU) and neonatal ICU (NICU)
重症监护病房(ICU)和新生儿重症监护病房(NICU)药品不良事件流行病学
  • 批准号:
    25860484
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Optimizing Adverse Drug Event Reporting within a Provincial Medication Information System to Improve Pharmacovigilence and Inform Pharmaceutical Policy
优化省级药品信息系统内的药品不良事件报告,以提高药物警戒并为药品政策提供信息
  • 批准号:
    284162
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Fellowship Programs
Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy
PharmaNet 中的药物不良事件报告可提高患者安全并为政策提供信息
  • 批准号:
    273419
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了